FDA Approved: DASATINIB — Supplemental Application (Prasco Laboratories)

View source ↗

Summary

FDA approved a supplemental application for dasatinib submitted by Prasco Laboratories, resulting in an approved change to its labeling and/or indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia
• Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Drugs mentioned

• DASATINIB (Dasatinib)

Snippet

SUPPL AP for DASATINIB (DASATINIB)